A health condition index for assessing disease progression. Issue 8 (3rd August 2022)

• Record Type: Journal Article
• Authors: Petridis, Dimitris; Matthaios, Dimitris; Christakidis, Vaggelis; Sardeli, Chrysanthi; Freitag, Lutz; Huang, Haidong; Zarogoulidis, Paul
• Is Part Of: Expert review of respiratory medicine. Volume 16:Issue 8(2022)
• Page Start: 867
• Page End: 873
• Publication Date: 2022-08-03
• Subjects: Lung cancer -- re-biopsy -- treatment -- nsclc; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Treatment -- Periodicals; 616.2005
• DOI: 10.1080/17476348.2022.2119132
• Languages: English
• ISSNs: 1747-6348

Abstract

ABSTRACT: Introduction: Currently immunotherapy is considered a cutting edge pharmaceutical treatment for non-small cell lung cancer. Tumor profile plays a crucial role in identifying the correct patient group. Methods: Therefore, initial biopsies and re-biopsies are necessary in order to identify the expression of programmed death-ligand-1. Results: This information is crucial and therefore all future immunotherapy studies have to be built upon a specific statistical model which associates the tumor profile and tumor profile expression along with treatment efficiency. Discussion: We present a novel statistical methodology for future immunotherapy studies of non-small cell lung cancer.